Trial Profile
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Glioma; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 05 Jul 2021 Planned End Date changed from 30 May 2023 to 21 Dec 2027.
- 05 Jul 2021 Planned primary completion date changed from 30 May 2023 to 20 Dec 2027.
- 23 Dec 2020 Planned End Date changed from 17 Jul 2023 to 30 May 2023.